Centessa Pharmaceuticals (CNTA) Operating Expenses (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Operating Expenses data on file, last reported at $79.8 million in Q1 2026.

• Quarterly Operating Expenses rose 74.26% year-over-year to $79.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $256.7 million (up 21.8% YoY) and the FY2025 annual result came in at $222.7 million, up 10.76% from the prior year.
• Operating Expenses climbed to $79.8 million in Q1 2026 per CNTA's latest filing, from $68.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $79.8 million in Q1 2026 and bottomed at $36.1 million in Q1 2024.
• The 5-year median for Operating Expenses is $48.9 million (2023), against an average of $52.5 million.
• The widest annual swing landed in 2022, when Operating Expenses jumped 225.59%; it then sank 31.27% in 2023.
• Tracing CNTA's Operating Expenses over 5 years: stood at $41.6 million in 2022, then grew by 1.03% to $42.0 million in 2023, then jumped by 77.44% to $74.6 million in 2024, then declined by 8.19% to $68.5 million in 2025, then climbed by 16.5% to $79.8 million in 2026.
• Per Business Quant, the three latest CNTA Operating Expenses figures stand at $79.8 million (Q1 2026), $68.5 million (Q4 2025), and $53.8 million (Q3 2025).

Peer Comparison